Cutaneous Fribrosis Treatment Market

Global Market Study on Cutaneous Fibrosis Treatment: Increasing Prevalence of Scleroderma & Keloids to fuel the demand for Cutaneous Fibrosis Treatment Drugs

The cutaneous Fibrosis Treatment Market is segmented by drug class, route of administration, indication, distribution channel, and region.

  • May-2022
  • PMRREP28039
  • 205 Pages
  • Healthcare
  • PPT, PDF, WORD, EXCEL

Cutaneous Fibrosis Treatment Market Outlook (2022 - 2029)

Cutaneous fibrosis is commonly seen in individuals who have keloids, GvHD, scleroderma, or have undergone radiation therapy. In the treatment of cutaneous fibrosis, corticosteroids, immunotherapy medicines, immunoglobulins, and anti-fibrotic medications are often used. During the forecast period of 2022 to 2029, the Global Cutaneous Fibrosis Treatment Market is estimated to witness a CAGR of 5%, and is estimated to reach US$ 771.4 million by 2029. Between 2013 and 2021, the Global Cutaneous Fibrosis Treatment Market had a CAGR of 6.3%.

Cutaneous Fibrosis Treatment Market Size (2022)

US$ 633.5 Mn

Projected Market Value (2029)

US$ 771.4 Mn

Global Market Growth Rate (2022-2026)

5% CAGR

Share in parent market

0.4%

Find Out More about the Report Coverage

Companies

  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • F. Hoffman - La Roche Ltd. (Genentech, Inc.)
  • Boehringer Ingelheim International GmbH
  • Jubilant Cadista
  • Horizon Pharma USA, Inc.
  • Bristol-Myers Squibb Company

Cutaneous Fibrosis Treatment Market Demand Analysis (2013-2021) v/s Market Outlook (2022-2029)

During the forecast period, the Global Cutaneous Fibrosis Treatment Market is expected to grow at a CAGR of 5%. The rise in the prevalence of cutaneous fibrosis-related skin disorders such as keloids, hypertrophic scars, and scleroderma is a prominent factor propelling the global cutaneous fibrosis treatment market. Furthermore, the increase in clinical trials to develop novel therapeutics for Cutaneous Fibrosis is likely to boost the growth of the Global Cutaneous Fibrosis Treatment Market.

Customize this Report

Explore Intelligence Tailored to Your Business Goals.

Growth Drivers for Cutaneous Fibrosis Treatment Market

  • An Increase in the Incidence of Cutaneous Fibrosis-Related Conditions

Cutaneous fibrosis is a rare autoimmune disease. The rising frequency of cutaneous fibrosis-related disorders such as scleroderma, keloids, and others is expected to propel the growth of the cutaneous fibrosis treatment market in the near future.

cutaneous-fibrosis-treatment-market

  • Increased Clinical Trials for Developing New Drugs for the Treatment Of Cutaneous Fibrosis

Scleroderma, keloids, and the other cutaneous fibrosis-related disorders are likely to fuel the growth of the cutaneous fibrosis therapy market. However, there is, at present, no authorized therapy for the treatment of cutaneous fibrosis. Since no therapy has been licensed for the treatment of cutaneous fibrosis, drug makers are undertaking research to discover and develop effective drugs for the treatment of cutaneous fibrosis. The unmet demands in cutaneous fibrosis treatment market indicate huge therapeutic and financial growth opportunities during the forecast period of 2022 to 2029.

Market Research Methodology - Perfected through Years of Diligence

A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.

Get actionable insights on Ship Repair And Maintenance Services Market

Restraints in the Cutaneous Fibrosis Treatment Market

  • “High Cost Of Treatment And Unavailability Of Medication”

Cutaneous fibrosis is a rare condition for which there is no approved treatment at present. The available therapies are not only unapproved but also very expensive. Many pharmaceutical companies are working on developing drugs for the treatment of Cutaneous fibrosis and some are now in clinical trials. Even if the treatments and medications are approved, they will most likely to cost a fortune due to the millions of dollars spent on research and development.

Explore Persistence Market Research’s expertise in promulgation of the business !

Impact of Covid-19 Pandemic

“Decrease in demand due to Covid-19”

The COVID-19 pandemic had an adverse effect on the Cutaneous Fibrotic Treatment market. The decrease in the number of appointments to hospitals and clinics for treatment by people suffering from the condition, particularly idiopathic pulmonary fibrosis, had an impact on the market between March 2020 and September 2021. These people were likely to be more vulnerable to COVID-19 infection, which further reduced the demand for fibrotic disease treatment. However, the number of patients receiving treatments increased again in 2021 as a result of the successful vaccination drives and the lifting up of Covid-19 restrictions.

Competitive Landscape

The global Cutaneous Fibrosis Treatment market is highly fragmented with number of regional as well as global players being involved. The market is mainly dominated by large pharma companies with vast as well as diverse product portfolios. Regional companies in the cutaneous fibrosis treatment market, on the other hand, possess a considerable market share, making the cutaneous fibrosis treatment market extremely fragmented. As there is no cure available, manufacturers in the market are focusing on developing novel cutaneous fibrosis treatment formulations. Market players currently compete based on their geographical product footprint, product offerings, and pricing of drugs in the same class.

Cutaneous Fibrosis Treatment Market Industry Report Scope

Attribute

Details

Forecast Period

2022-2029

Historical Data Available for

2013-2021

Market Analysis

US$ Mn/Bn for Value

Key Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Key Countries Covered

  • U.S.
  • Canada
  • Germany
  • Italy
  • France
  • U.K.
  • Spain
  • Russia
  • India
  • China
  • Japan
  • UAE
  • Australia

Key Market Segments Covered

By Drug Class

Key Companies Profiled

  • Pfizer Inc.
  • Sanofi
  • F. Hoffman - La Roche Ltd. (Genentech, Inc.)
  • Boehringer Ingelheim International GmbH
  • Jubilant Cadista
  • Horizon Pharma USA, Inc.
  • Bristol-Myers Squibb Company

Customization & Pricing

Available upon Request

Cutaneous Fibrosis Treatment Market Categorization

Cutaneous Fibrosis Treatment Market by Drug Class

  • Corticosteroids
  • Anti-fibrotic Drugs
  • Immunotherapy
  • Immunoglobulins

Cutaneous Fibrosis Treatment Market by Route of Administration

  • Oral
  • Injectables
  • Topical

Cutaneous Fibrosis Treatment Market by Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa (MEA)

Media Release

- FAQs -

In 2022, the Cutaneous Fibrosis Treatment Market stands at USD 633.5 million, and it is expected to reach USD 771.4 million by 2029 at a CAGR of 5%.

Cutaneous Fibrosis Treatment Market exhibited a 6.3% CAGR between 2013 and 2021.

High cost of treatment and unavailability of medication are the key restraints in the Cutaneous Fibrosis Treatment Market.

An increase in the incidence of Cutaneous Fibrosis-related conditions is the key factor driving the growth of the market.

Pfizer Inc., Sanofi, Jubilant Cadista, and Horizon Pharma USA, Inc. are among the top players in the market.

Recommendations

Biologics Contract Manufacturing Demand

PMR’s study on biologics contract manufacturing demand offers information divided into five important segments— product, platform, application, therapeutic area & regional outlook.

Progressive Multifocal Leukoencephalopathy Treatment Market

The global progressive multifocal leukoencephalopathy treatment market is projected to grow at a CAGR of 2.8% throughout the forecast period, Growing prevalence of HIV infection in several middles- and low-income economies is consequently expected to drive the growth of the market for progressive multifocal leukoencephalopathy treatment over the forecast period..

Rheumatoid Arthritis Treatment Market

Rheumatoid Arthritis Treatment Market is expected to reach a market value of over US$ 30,000 Mn by the end of 2025, growing at a CAGR of 6.2% during the forecast period..

Immune Checkpoint Inhibitors Market

Expanding at a booming CAGR of 14.6%, the global market for immune checkpoint inhibitors market is expected to reach a value beyond US$ 35 Bn over 2018-2026..

Our Clients

Our Clients